MeSH term
Frequency | Condition_Probility | Aged | 23 | 0.0 |
Aged, 80 and over | 9 | 0.0 |
English Abstract | 2 | 0.0 |
Female | 76 | 0.0 |
Humans | 402 | 0.0 |
Male | 68 | 0.0 |
Middle Aged | 42 | 0.0 |
Gene Library | 2 | 0.0 |
*Genome, Human | 2 | 0.0 |
Molecular Sequence Data | 70 | 0.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Polymerase Chain Reaction | 24 | 0.0 |
*Polymorphism, Genetic | 7 | 0.0 |
Research Support, Non-U.S. Gov't | 301 | 0.0 |
Adolescent | 17 | 0.0 |
Adult | 69 | 0.0 |
Chemokines, CC/*blood | 2 | 20.0 |
Child | 11 | 0.0 |
Child, Preschool | 9 | 0.0 |
Severity of Illness Index | 3 | 0.0 |
Animals | 118 | 0.0 |
Mice | 51 | 0.0 |
Microspheres | 2 | 1.0 |
Models, Immunological | 3 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 10 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 132 | 0.0 |
Transcription, Genetic | 5 | 0.0 |
Amino Acid Sequence | 57 | 0.0 |
Binding, Competitive | 15 | 0.0 |
Calcium/metabolism | 39 | 2.0 |
Cell Line | 69 | 0.0 |
Chemotaxis | 13 | 7.0 |
Cloning, Molecular | 16 | 0.0 |
Eosinophils/physiology | 2 | 15.0 |
Macaca mulatta | 9 | 2.0 |
Mice, Inbred BALB C | 11 | 0.0 |
Base Sequence | 28 | 0.0 |
Cells, Cultured | 75 | 0.0 |
Comparative Study | 31 | 0.0 |
Fluorescent Antibody Technique | 4 | 0.0 |
HIV-1/*metabolism | 6 | 2.0 |
RNA, Messenger/analysis | 14 | 0.0 |
Receptors, Chemokine/genetics/*metabolism | 6 | 12.0 |
Reverse Transcriptase Polymerase Chain Reaction | 27 | 0.0 |
SIV/metabolism | 2 | 28.0 |
Sequence Alignment | 13 | 0.0 |
Virus Replication | 29 | 3.0 |
Eosinophils/metabolism | 7 | 25.0 |
*Gene Expression Regulation | 2 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
RNA, Messenger | 2 | 0.0 |
Receptors, Chemokine/*genetics/metabolism | 4 | 28.0 |
Sequence Analysis, DNA | 5 | 0.0 |
Chemotaxis, Leukocyte/drug effects | 11 | 13.0 |
Dose-Response Relationship, Drug | 18 | 0.0 |
Receptors, Chemokine/*antagonists & inhibitors | 6 | 35.0 |
Reference Values | 2 | 0.0 |
Up-Regulation/drug effects | 6 | 1.0 |
Chemokines, CC/metabolism | 2 | 4.0 |
Ligands | 29 | 1.0 |
Structure-Activity Relationship | 13 | 0.0 |
Flow Cytometry | 37 | 0.0 |
RNA, Messenger/metabolism | 10 | 0.0 |
Receptors, Chemokine/*biosynthesis/genetics | 13 | 44.0 |
Calcium/blood | 4 | 1.0 |
Lymphocytes/immunology | 2 | 0.0 |
Phylogeny | 10 | 0.0 |
RANTES/genetics | 4 | 26.0 |
Sequence Homology, Amino Acid | 20 | 0.0 |
DNA Primers | 12 | 0.0 |
HIV-1/*genetics | 3 | 0.0 |
Phenotype | 18 | 0.0 |
Antigens, Dermatophagoides | 2 | 3.0 |
Chemokines/biosynthesis/genetics | 2 | 11.0 |
Chemokines, CC/*biosynthesis | 2 | 10.0 |
Chemotaxis, Leukocyte | 13 | 7.0 |
Glycoproteins/immunology | 2 | 2.0 |
Hypersensitivity/*immunology | 4 | 8.0 |
Receptors, Chemokine/genetics | 2 | 4.0 |
Th2 Cells/*immunology | 11 | 8.0 |
Asthma/immunology | 4 | 11.0 |
Chemokines/*physiology | 6 | 19.0 |
Cytokines/*physiology | 5 | 2.0 |
Th2 Cells/immunology | 13 | 8.0 |
Antigens, CD4/*metabolism | 3 | 0.0 |
Macrophages/metabolism | 4 | 1.0 |
Rats | 14 | 0.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
Receptors, CCR5/*metabolism | 13 | 8.0 |
Receptors, CXCR4/*metabolism | 9 | 5.0 |
Receptors, Chemokine/*metabolism | 47 | 33.0 |
Receptors, HIV/metabolism | 8 | 25.0 |
CD4-Positive T-Lymphocytes/immunology/metabolism | 3 | 4.0 |
Chemokines, CC/*metabolism | 11 | 20.0 |
Immunohistochemistry | 24 | 0.0 |
*Up-Regulation | 2 | 0.0 |
Down-Regulation/*drug effects | 2 | 3.0 |
Time Factors | 18 | 0.0 |
Antigens, CD/metabolism | 4 | 0.0 |
Enzyme Inhibitors/pharmacology | 5 | 0.0 |
Eosinophils/drug effects/*metabolism | 2 | 33.0 |
Imidazoles/pharmacology | 2 | 0.0 |
Pertussis Toxin | 4 | 2.0 |
Pyridines/pharmacology | 3 | 1.0 |
Respiratory Burst | 3 | 4.0 |
Up-Regulation | 5 | 0.0 |
Virulence Factors, Bordetella/pharmacology | 6 | 3.0 |
p38 Mitogen-Activated Protein Kinases | 2 | 0.0 |
Chemotactic Factors, Eosinophil/*physiology | 2 | 66.0 |
Chemotaxis, Leukocyte/*immunology | 4 | 8.0 |
Drug Combinations | 3 | 0.0 |
Receptors, Chemokine/*physiology | 10 | 24.0 |
Signal Transduction/immunology | 4 | 1.0 |
Up-Regulation/immunology | 7 | 4.0 |
Asthma/*drug therapy/immunology | 2 | 20.0 |
Cytokines/*antagonists & inhibitors | 3 | 20.0 |
*Monokines | 2 | 100.0 |
NF-kappa B/metabolism | 2 | 0.0 |
Signal Transduction/drug effects/physiology | 2 | 0.0 |
Tumor Cells, Cultured | 21 | 0.0 |
HIV-1/genetics/*physiology | 5 | 4.0 |
Immunophenotyping | 9 | 0.0 |
Pregnancy | 8 | 0.0 |
Receptors, CXCR4/metabolism | 16 | 10.0 |
Receptors, Chemokine/metabolism | 18 | 15.0 |
Transfection | 35 | 0.0 |
Variation (Genetics) | 10 | 0.0 |
*Virus Replication | 3 | 1.0 |
Astrocytes/cytology/virology | 2 | 50.0 |
CD4 Lymphocyte Count | 3 | 0.0 |
Disease Progression | 7 | 0.0 |
Disease Transmission, Vertical | 5 | 5.0 |
Infant | 7 | 0.0 |
Receptors, CCR5/metabolism | 23 | 15.0 |
Receptors, HIV/*metabolism | 10 | 15.0 |
Viral Load | 3 | 0.0 |
Antigens, CD4/analysis | 3 | 0.0 |
In Situ Hybridization | 4 | 0.0 |
*Intercellular Signaling Peptides and Proteins | 2 | 0.0 |
Receptors, Chemokine/analysis | 5 | 16.0 |
Amino Acid Motifs | 2 | 0.0 |
Amino Acid Substitution | 3 | 0.0 |
Binding Sites | 5 | 0.0 |
Chemokines, CC/pharmacology | 4 | 12.0 |
Chemotaxis/drug effects | 5 | 5.0 |
Models, Molecular | 10 | 0.0 |
Mutagenesis, Site-Directed | 5 | 0.0 |
Protein Conformation | 6 | 0.0 |
Recombinant Proteins/pharmacology | 7 | 0.0 |
Cats | 2 | 0.0 |
Leukocytes, Mononuclear/virology | 8 | 7.0 |
Macaca | 3 | 3.0 |
Receptors, Chemokine/chemistry/genetics/*metabolism | 2 | 40.0 |
Disease Models, Animal | 5 | 0.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
Interferon Type II/metabolism | 2 | 0.0 |
Interleukin-4/metabolism | 2 | 2.0 |
Mice, Inbred CBA | 2 | 0.0 |
Anti-HIV Agents/*pharmacology | 6 | 4.0 |
Chemokines, CC/*pharmacology | 6 | 28.0 |
Down-Regulation/drug effects | 5 | 1.0 |
Macrophages/*virology | 6 | 10.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Peptide Fragments/*pharmacology | 2 | 1.0 |
Protein Binding | 11 | 0.0 |
RANTES/pharmacology | 15 | 28.0 |
Receptors, CCR5/*antagonists & inhibitors | 2 | 5.0 |
T-Lymphocytes/*virology | 5 | 9.0 |
Virus Replication/drug effects | 8 | 3.0 |
Androstadienes/pharmacology | 2 | 0.0 |
Antibodies, Monoclonal/pharmacology | 7 | 0.0 |
Cell Membrane/immunology/metabolism | 2 | 1.0 |
Down-Regulation/genetics/*immunology | 2 | 10.0 |
Interleukin-4/biosynthesis | 7 | 4.0 |
Mice, Knockout | 4 | 0.0 |
Ovalbumin/immunology | 2 | 4.0 |
Receptors, Chemokine/immunology/*metabolism | 2 | 20.0 |
Basophils/*immunology | 2 | 9.0 |
Flow Cytometry/methods | 2 | 0.0 |
Receptors, Chemokine/*immunology | 10 | 35.0 |
Sensitivity and Specificity | 3 | 0.0 |
Mutagenesis | 4 | 0.0 |
Receptors, Chemokine/*agonists | 3 | 60.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Cell Differentiation | 11 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Gene Expression Regulation | 6 | 0.0 |
Lymphocyte Activation | 8 | 0.0 |
Receptors, Chemokine/*genetics/*metabolism | 3 | 42.0 |
Tissue Distribution | 2 | 0.0 |
Biological Markers/analysis | 4 | 0.0 |
Interferon Type II/pharmacology | 8 | 1.0 |
RANTES/*biosynthesis | 3 | 25.0 |
Antibodies/pharmacology | 2 | 0.0 |
Cell Degranulation | 2 | 4.0 |
Cell Survival/drug effects | 2 | 0.0 |
Chemotactic Factors/*pharmacology | 2 | 5.0 |
*Chemotaxis, Leukocyte | 6 | 8.0 |
Kinetics | 11 | 0.0 |
CD4-Positive T-Lymphocytes/immunology | 4 | 0.0 |
Interleukin-5/immunology | 6 | 37.0 |
Receptors, Chemokine/*analysis | 10 | 27.0 |
Chemokines/*metabolism | 7 | 12.0 |
Chemokines, CXC/metabolism | 2 | 2.0 |
Liver/pathology | 2 | 1.0 |
Receptors, Cytokine/metabolism | 4 | 4.0 |
Monocytes/cytology/drug effects/*immunology | 3 | 18.0 |
Receptors, CCR5/biosynthesis | 3 | 7.0 |
Receptors, Chemokine/biosynthesis | 6 | 12.0 |
Antigens, CD3/analysis | 3 | 1.0 |
Arthritis, Rheumatoid/*immunology | 3 | 1.0 |
Biopsy | 5 | 0.0 |
Cross-Sectional Studies | 4 | 0.0 |
Longitudinal Studies | 6 | 0.0 |
RNA, Messenger/biosynthesis | 14 | 0.0 |
T-Lymphocytes/immunology | 7 | 0.0 |
Antigens, CD34/*immunology | 2 | 2.0 |
Cell Movement | 12 | 1.0 |
Receptors, Chemokine/*biosynthesis | 14 | 35.0 |
Monocyte Chemoattractant Protein-1/analysis | 2 | 20.0 |
Receptors, CCR5/analysis | 8 | 16.0 |
Adjuvants, Immunologic/pharmacology | 2 | 2.0 |
In Vitro | 21 | 0.0 |
Antibodies, Monoclonal/immunology | 5 | 0.0 |
Case-Control Studies | 4 | 0.0 |
Cell Count | 3 | 0.0 |
Statistics, Nonparametric | 4 | 0.0 |
HIV-1/*physiology | 19 | 4.0 |
Hela Cells | 9 | 0.0 |
Receptors, CCR5/analysis/physiology | 2 | 50.0 |
Receptors, Chemokine/physiology | 6 | 23.0 |
Acute Disease | 4 | 0.0 |
HIV-1/*isolation & purification | 2 | 2.0 |
Prognosis | 3 | 0.0 |
Brain/*virology | 3 | 25.0 |
Microglia/*virology | 2 | 40.0 |
Receptors, CXCR4/physiology | 7 | 15.0 |
Receptors, HIV/*physiology | 10 | 27.0 |
Receptors, Chemokine/*analysis/physiology | 2 | 40.0 |
*Receptors, Prostaglandin | 2 | 33.0 |
Th2 Cells/*chemistry | 2 | 66.0 |
Lymphocyte Count | 3 | 0.0 |
Monocytes/immunology | 3 | 0.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
Cell Separation | 4 | 0.0 |
Calcium Signaling/drug effects | 6 | 12.0 |
*Chemokines, CC | 35 | 47.0 |
Cytokines/pharmacology | 14 | 3.0 |
Endocytosis/drug effects | 3 | 4.0 |
Gene Expression Regulation/drug effects | 4 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 2 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 8 | 0.0 |
Protein Processing, Post-Translational/drug effects | 2 | 1.0 |
HIV Envelope Protein gp120/genetics | 4 | 11.0 |
Receptors, CCR5/*immunology | 3 | 16.0 |
Chromosomes, Human, Pair 17 | 2 | 0.0 |
HIV Infections/therapy | 2 | 13.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Actins/metabolism | 3 | 0.0 |
Antigens, CD4/metabolism | 9 | 2.0 |
Receptors, CXCR4/genetics/metabolism | 6 | 24.0 |
Cell Division/drug effects | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 6 | 0.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
Eosinophils/immunology | 8 | 15.0 |
Interleukin-4/physiology | 2 | 5.0 |
Interleukin-5/physiology | 2 | 20.0 |
Aorta/pathology | 2 | 5.0 |
Mice, Transgenic | 4 | 0.0 |
Receptors, Chemokine/genetics/metabolism | 4 | 17.0 |
Chemokines/physiology | 3 | 11.0 |
Microscopy, Electron | 3 | 0.0 |
Antigens, CD4/immunology | 3 | 1.0 |
Cytopathogenic Effect, Viral | 4 | 2.0 |
Immune Sera/pharmacology | 2 | 2.0 |
Macrophages/virology | 11 | 14.0 |
Receptors, CCR5/immunology | 2 | 10.0 |
Receptors, Chemokine/immunology | 5 | 15.0 |
T-Lymphocytes/virology | 7 | 10.0 |
U937 Cells | 5 | 1.0 |
Interleukin-1/pharmacology | 6 | 0.0 |
RANTES/*genetics | 2 | 14.0 |
Receptors, CCR5/genetics | 6 | 9.0 |
CHO Cells | 12 | 0.0 |
Calcium Signaling | 7 | 8.0 |
HIV-1/*drug effects | 3 | 2.0 |
Hamsters | 14 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Receptors, HIV/physiology | 4 | 25.0 |
Inflammation | 6 | 1.0 |
Cell Movement/immunology | 7 | 7.0 |
Interleukin-4/*biosynthesis | 2 | 3.0 |
Receptors, CCR5/*biosynthesis | 3 | 12.0 |
Th1 Cells/*immunology | 7 | 5.0 |
Gene Expression Regulation, Viral | 2 | 0.0 |
HIV Infections/*immunology/virology | 2 | 3.0 |
HIV-1/immunology/*physiology | 2 | 3.0 |
Histamine Release | 2 | 3.0 |
Receptors, Chemokine/biosynthesis/genetics/*physiology | 2 | 50.0 |
Th1 Cells/immunology | 5 | 2.0 |
Immunization | 4 | 1.0 |
RNA, Messenger/biosynthesis/genetics | 3 | 0.0 |
Giant Cells | 3 | 5.0 |
HIV-1/genetics/*metabolism | 2 | 2.0 |
Peptide Fragments/genetics | 2 | 2.0 |
Gene Expression | 12 | 0.0 |
HIV-1/physiology | 4 | 4.0 |
Protein Structure, Tertiary | 5 | 0.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Chemotaxis, Leukocyte/*drug effects | 5 | 7.0 |
Cyclic AMP-Dependent Protein Kinases/metabolism | 2 | 1.0 |
Eosinophils/drug effects/*immunology | 2 | 22.0 |
Monocyte Chemoattractant Proteins/pharmacology | 7 | 63.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
Asthma/*immunology | 5 | 5.0 |
Endothelium, Vascular/*metabolism | 2 | 0.0 |
Eosinophils/*immunology | 6 | 10.0 |
Integrin alpha4 | 2 | 5.0 |
Receptors, Chemokine/immunology/physiology | 2 | 100.0 |
Injections, Subcutaneous | 2 | 0.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Bronchial Provocation Tests | 2 | 2.0 |
Cell Polarity | 2 | 1.0 |
Th2 Cells/*immunology/metabolism | 8 | 29.0 |
Receptors, Chemokine/*antagonists & inhibitors/metabolism | 5 | 41.0 |
Monocyte Chemoattractant Protein-1/metabolism | 6 | 9.0 |
RANTES/antagonists & inhibitors/metabolism | 2 | 100.0 |
Cytokines/*immunology | 3 | 3.0 |
Eosinophils/*physiology | 4 | 9.0 |
Cytokines/metabolism | 4 | 0.0 |
RANTES/antagonists & inhibitors | 2 | 33.0 |
Macrophages/immunology/metabolism | 3 | 6.0 |
Monocytes/immunology/metabolism | 3 | 6.0 |
RANTES/immunology/metabolism | 2 | 50.0 |
Receptors, Chemokine/*biosynthesis/immunology | 3 | 60.0 |
Synovial Fluid/cytology/immunology/*metabolism | 2 | 50.0 |
*Genome, Viral | 2 | 2.0 |
HIV-1/classification/*genetics | 2 | 9.0 |
Chemokines, CXC/pharmacology | 6 | 8.0 |
Coculture Techniques | 3 | 0.0 |
Fetus | 5 | 0.0 |
HIV-1/metabolism/*pathogenicity | 2 | 11.0 |
Macrophage Inflammatory Protein-1/pharmacology | 8 | 18.0 |
Receptors, CCR5/*genetics/metabolism | 2 | 12.0 |
HIV Infections/*immunology | 5 | 1.0 |
HIV-1/*immunology | 7 | 1.0 |
Interleukin-13/secretion | 3 | 42.0 |
Interleukin-4/secretion | 3 | 7.0 |
Mast Cells/*immunology | 2 | 7.0 |
Th1 Cells | 2 | 16.0 |
Th2 Cells | 2 | 13.0 |
Cell Proliferation | 2 | 1.0 |
Cell Line, Tumor | 4 | 0.0 |
HIV Infections/*virology | 2 | 2.0 |
Receptors, Peptide/metabolism | 2 | 6.0 |
Receptors, Virus/metabolism | 3 | 4.0 |
Viremia/*virology | 2 | 12.0 |
Alleles | 3 | 0.0 |
Genetics, Population | 2 | 0.0 |
Japan | 2 | 0.0 |
Mutation | 4 | 0.0 |
Receptors, Chemokine/*genetics | 14 | 14.0 |
Reactive Oxygen Species/metabolism | 3 | 0.0 |
Chronic Disease | 3 | 0.0 |
Interleukin-4/pharmacology | 3 | 0.0 |
Threonine/chemistry | 2 | 2.0 |
Cell Adhesion | 2 | 0.0 |
Eosinophils | 2 | 5.0 |
Interleukin-5/*physiology | 3 | 33.0 |
Signal Transduction | 7 | 0.0 |
B-Lymphocytes/immunology | 2 | 0.0 |
Interleukin-3/pharmacology | 2 | 0.0 |
Antibodies, Monoclonal/immunology/pharmacology | 2 | 2.0 |
Osmolar Concentration | 2 | 0.0 |
Polymers/metabolism | 2 | 4.0 |
Chimera | 2 | 1.0 |
Receptors, CCR5/*physiology | 5 | 12.0 |
Receptors, CXCR4/*physiology | 2 | 4.0 |
Drug Synergism | 5 | 0.0 |
Hypersensitivity/physiopathology | 2 | 66.0 |
Monocyte Chemoattractant Protein-1/pharmacology | 3 | 14.0 |
Receptors, CCR5/*agonists | 2 | 100.0 |
Chemokines/*immunology | 6 | 31.0 |
Inflammation/*immunology | 3 | 5.0 |
Leukocytes/*immunology | 2 | 1.0 |
HIV Infections/virology | 2 | 2.0 |
HIV-1/metabolism | 2 | 4.0 |
*Receptors, G-Protein-Coupled | 10 | 3.0 |
*Receptors, Virus | 5 | 20.0 |
CD8-Positive T-Lymphocytes/*immunology | 2 | 0.0 |
Clone Cells | 6 | 0.0 |
Cytokines/*biosynthesis | 4 | 1.0 |
Immunologic Memory | 9 | 3.0 |
Th1 Cells/*immunology/metabolism | 2 | 9.0 |
DNA Primers/genetics | 7 | 0.0 |
RNA, Messenger/genetics/metabolism | 7 | 0.0 |
Basophils/immunology | 3 | 15.0 |
Chemokines/*pharmacology | 7 | 25.0 |
Cytokines/biosynthesis | 5 | 0.0 |
Macrophages/immunology | 2 | 0.0 |
Skin Transplantation | 2 | 7.0 |
Carrier Proteins/metabolism | 2 | 0.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
Receptors, Cell Surface/metabolism | 2 | 0.0 |
Th1 Cells/metabolism | 2 | 7.0 |
Infant, Newborn | 4 | 0.0 |
Arthritis, Rheumatoid/immunology | 2 | 2.0 |
RNA, Messenger/analysis/biosynthesis | 2 | 0.0 |
Receptors, Chemokine/biosynthesis/*genetics | 2 | 66.0 |
Chemokines/pharmacology | 6 | 18.0 |
Bone Marrow Cells/*immunology | 3 | 11.0 |
Cell Differentiation/immunology | 6 | 1.0 |
Trans-Activators/metabolism | 2 | 0.0 |
Interleukin-4/*pharmacology | 2 | 0.0 |
Calcium Signaling/immunology | 5 | 22.0 |
Chemokines, CC/*metabolism/pharmacology | 2 | 33.0 |
Intracellular Fluid/metabolism | 2 | 1.0 |
*Chromosomes, Human, Pair 3 | 3 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Down-Regulation | 3 | 0.0 |
Gene Deletion | 4 | 0.0 |
Hybrid Cells | 3 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Mice, SCID | 3 | 0.0 |
Chemotaxis, Leukocyte/immunology | 5 | 8.0 |
Up-Regulation/*immunology | 4 | 7.0 |
DNA, Complementary/biosynthesis | 2 | 3.0 |
T-Lymphocytes/*metabolism | 2 | 0.0 |
Lipopolysaccharides/pharmacology | 5 | 0.0 |
Receptors, CXCR4/analysis | 3 | 8.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
*Cytokines | 3 | 7.0 |
Eosinophils/cytology/metabolism | 2 | 50.0 |
Signal Transduction/*immunology | 3 | 0.0 |
Antigens, CD4/*physiology | 2 | 1.0 |
CD4-Positive T-Lymphocytes/virology | 2 | 2.0 |
Receptors, CCR5/genetics/physiology | 2 | 28.0 |
Receptors, CXCR4/genetics/physiology | 3 | 50.0 |
Receptors, Virus/*physiology | 2 | 5.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
Blotting, Western | 2 | 0.0 |
Peptide Fragments/pharmacology | 2 | 0.0 |
Phosphorylation/drug effects | 4 | 0.0 |
Receptors, CXCR4/*biosynthesis/genetics | 2 | 18.0 |
Chemokines, CXC/*pharmacology | 2 | 6.0 |
Receptors, Chemokine/*agonists/*antagonists & inhibitors/metabolism | 2 | 100.0 |
Th2 Cells/metabolism | 3 | 7.0 |
Interferon Type II/genetics | 2 | 2.0 |
Receptors, Chemokine/genetics/*immunology | 2 | 20.0 |
Acquired Immunodeficiency Syndrome/*virology | 5 | 25.0 |
Evolution, Molecular | 4 | 0.0 |
Injections, Intradermal | 2 | 4.0 |
Blood Proteins/*metabolism | 2 | 1.0 |
Endopeptidases/metabolism | 2 | 1.0 |
Organ Specificity | 5 | 0.0 |
Gene Expression/immunology | 2 | 2.0 |
Receptors, Chemokine/*genetics/*immunology | 2 | 100.0 |
Antigens, CD45/analysis | 2 | 0.0 |
Interferon Type II/biosynthesis/genetics | 2 | 5.0 |
Interleukin-4/biosynthesis/genetics | 2 | 11.0 |
Receptors, CCR5/*biosynthesis/genetics | 2 | 13.0 |
Blotting, Northern | 2 | 0.0 |
Eosinophils/*metabolism | 2 | 6.0 |
Open Reading Frames | 2 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Eosinophils/*cytology | 2 | 15.0 |
Eosinophils/*drug effects | 2 | 18.0 |
Receptors, HIV/*antagonists & inhibitors | 2 | 28.0 |
Molecular Structure | 4 | 0.0 |
Receptors, Interleukin/immunology | 2 | 16.0 |
Neutrophils/physiology | 2 | 1.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Protein Structure, Secondary | 3 | 0.0 |
Receptors, Chemokine/*chemistry/*metabolism | 3 | 75.0 |
Thermodynamics | 2 | 0.0 |
Antibody Specificity | 2 | 0.0 |
Recurrence | 3 | 0.0 |
Heterocyclic Compounds/pharmacology | 3 | 12.0 |
Receptors, HIV/antagonists & inhibitors/*metabolism | 2 | 100.0 |
Models, Biological | 4 | 0.0 |
Interferon-gamma, Recombinant/*pharmacology | 2 | 1.0 |
Receptors, CXCR4/*biosynthesis | 2 | 6.0 |
Follow-Up Studies | 2 | 0.0 |
RNA, Viral/analysis | 3 | 1.0 |
Receptors, Cytokine/*metabolism | 7 | 8.0 |
HIV Infections/immunology/pathology/*virology | 2 | 33.0 |
HIV-1/*pathogenicity | 5 | 5.0 |
Chemotaxis, Leukocyte/drug effects/*physiology | 4 | 20.0 |
Eosinophils/drug effects/*physiology | 2 | 20.0 |
Cell Division | 4 | 0.0 |
Cell Membrane/metabolism | 4 | 0.0 |
Chemokines/metabolism | 4 | 5.0 |
Chick Embryo | 2 | 0.0 |
Models, Chemical | 2 | 0.0 |
Synovial Membrane/*immunology | 2 | 5.0 |
T-Lymphocyte Subsets/immunology | 2 | 0.0 |
Chemokines, CC/physiology | 3 | 23.0 |
Neutrophils/drug effects/physiology | 2 | 9.0 |
Rabbits | 3 | 0.0 |
*Viral Proteins | 2 | 1.0 |
Monocyte Chemoattractant Protein-1/*metabolism | 3 | 9.0 |
Signal Transduction/physiology | 2 | 0.0 |
Databases, Factual | 2 | 0.0 |
Integrins/metabolism | 2 | 1.0 |
Chemotactic Factors, Eosinophil/metabolism/pharmacology | 2 | 100.0 |
Monocyte Chemoattractant Proteins/metabolism/pharmacology | 2 | 100.0 |
RANTES/metabolism/pharmacology | 3 | 37.0 |
Cell Movement/*immunology | 3 | 4.0 |
Dose-Response Relationship, Immunologic | 6 | 1.0 |
Umbilical Veins | 2 | 0.0 |
Anti-HIV Agents/pharmacology | 2 | 4.0 |
RANTES/*analogs & derivatives/pharmacology | 2 | 33.0 |
Cytokines/*biosynthesis/genetics | 2 | 2.0 |
DNA, Complementary | 3 | 0.0 |
Receptors, Cytokine/genetics | 3 | 9.0 |
Brain/*blood supply | 2 | 6.0 |
Cell Migration Inhibition | 3 | 2.0 |
Adoptive Transfer | 2 | 2.0 |
Allergens/immunology | 3 | 4.0 |
CD8-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Chemokines/*biosynthesis | 5 | 16.0 |
HIV Infections/*metabolism | 2 | 4.0 |
*HIV-1 | 4 | 0.0 |
DNA, Viral/biosynthesis | 3 | 5.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Chromosomes, Human, Pair 3/genetics | 2 | 1.0 |
Genetic Markers | 2 | 0.0 |
Monocytes/metabolism | 2 | 0.0 |
Neuroglia/metabolism | 2 | 2.0 |
Receptors, Chemokine/metabolism/*physiology | 4 | 44.0 |
SIV/*pathogenicity | 2 | 12.0 |
Tyrosine/metabolism | 2 | 0.0 |
Glomerular Mesangium/*metabolism | 2 | 20.0 |
AIDS Dementia Complex/*etiology/genetics/virology | 2 | 100.0 |
Gene Products, tat/metabolism | 2 | 5.0 |
Genotype | 9 | 0.0 |
Heterozygote | 3 | 0.0 |
Receptors, CCR5/*genetics | 5 | 3.0 |
Chemokines/*biosynthesis/genetics | 2 | 14.0 |
Macrophage Inflammatory Protein-1/metabolism | 3 | 5.0 |
RANTES/metabolism | 7 | 11.0 |
Receptors, CCR5/genetics/metabolism | 5 | 19.0 |
Receptors, Cytokine/genetics/metabolism | 2 | 16.0 |
Receptors, HIV/genetics/*metabolism | 3 | 15.0 |
Dogs | 4 | 0.0 |
Receptors, Virus/*metabolism | 4 | 4.0 |
Eosinophil Granule Proteins | 2 | 0.0 |
*Ribonucleases | 2 | 0.0 |
Chemokines/metabolism/*physiology | 2 | 66.0 |
Chemokines, CC/pharmacology/physiology | 2 | 50.0 |
Cricetulus | 2 | 0.0 |
Monocyte Chemoattractant Protein-1/pharmacology/physiology | 2 | 100.0 |
Radioligand Assay | 7 | 1.0 |
Quinolinic Acid/*pharmacology | 2 | 40.0 |
Chromosome Mapping | 2 | 0.0 |
Multigene Family | 2 | 0.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
*Apoptosis | 2 | 0.0 |
CD4-Positive T-Lymphocytes/metabolism | 2 | 1.0 |
CD8-Positive T-Lymphocytes/metabolism | 2 | 2.0 |
Homozygote | 3 | 0.0 |
Immunity, Natural | 2 | 0.0 |
Receptors, CXCR4/genetics | 2 | 10.0 |
Receptors, CCR5/physiology | 4 | 12.0 |
Receptors, Chemokine/*biosynthesis/physiology | 3 | 33.0 |
GTP-Binding Proteins/metabolism | 3 | 1.0 |
Chemotactic Factors, Eosinophil/*pharmacology | 2 | 50.0 |
Cytokines/*pharmacology | 3 | 0.0 |
Hypersensitivity/immunology | 3 | 7.0 |
Ethiopia | 2 | 7.0 |
HIV Envelope Protein gp120/*genetics | 3 | 12.0 |
RNA, Viral/blood | 2 | 0.0 |
Mites/*immunology | 2 | 4.0 |
Cell Differentiation/drug effects | 4 | 0.0 |
Fetal Blood/cytology | 2 | 1.0 |
Chemotaxis/*drug effects | 3 | 6.0 |
Biological Markers | 2 | 0.0 |
*Receptors, Chemokine | 12 | 12.0 |
Eosinophils/pathology | 2 | 5.0 |
Receptors, Chemokine/*analysis/genetics | 2 | 25.0 |
Cell Line, Transformed | 6 | 0.0 |
Genes, env | 5 | 8.0 |
Receptors, Interleukin/metabolism | 4 | 6.0 |
Receptors, Interleukin-8A | 3 | 9.0 |
Antigens, CD4/physiology | 4 | 4.0 |
Brain/cytology/*virology | 2 | 66.0 |
Point Mutation | 2 | 0.0 |
Fetal Blood/cytology/immunology | 3 | 8.0 |
Receptors, Antigen, T-Cell/*metabolism | 2 | 1.0 |
Receptors, Lymphocyte Homing/metabolism | 2 | 5.0 |
T-Lymphocytes/*immunology/metabolism | 2 | 1.0 |
3T3 Cells | 3 | 0.0 |
Cell Fusion | 3 | 1.0 |
Th2 Cells/*metabolism | 2 | 8.0 |
DNA, Viral/analysis | 2 | 0.0 |
Jurkat Cells | 3 | 0.0 |
Protein Binding/drug effects | 3 | 0.0 |
Macrophages, Alveolar/metabolism/*virology | 2 | 50.0 |
Species Specificity | 2 | 0.0 |
Asthma/*immunology/pathology | 2 | 15.0 |
Eosinophils/*immunology/pathology | 2 | 40.0 |
Binding Sites/immunology | 2 | 3.0 |
Intercellular Adhesion Molecule-1/metabolism | 2 | 1.0 |
T-Lymphocyte Subsets/immunology/*metabolism | 3 | 8.0 |
Neurons/metabolism | 2 | 0.0 |
Eosinophils/*drug effects/physiology | 3 | 75.0 |
Kidney | 2 | 0.0 |
RNA, Messenger/blood | 2 | 3.0 |
HIV Envelope Protein gp120/*physiology | 2 | 6.0 |
HIV-2/*physiology | 3 | 13.0 |
Virulence | 2 | 0.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Interferon Type II/*pharmacology | 2 | 0.0 |
Eosinophils/cytology/*metabolism | 2 | 33.0 |
Interleukin-8/metabolism | 2 | 1.0 |
Receptors, Chemokine/*biosynthesis/blood/genetics | 2 | 100.0 |
Receptors, Interleukin-8B | 2 | 18.0 |
Cell Movement/physiology | 3 | 1.0 |
RANTES/*immunology | 2 | 50.0 |
Receptors, CCR5/biosynthesis/genetics | 4 | 44.0 |
Receptors, Chemokine/biosynthesis/genetics | 3 | 16.0 |
Th1 Cells/immunology/*metabolism | 2 | 25.0 |
Th2 Cells/immunology/*metabolism | 2 | 16.0 |
HIV-1/genetics/*pathogenicity/*physiology | 2 | 33.0 |
Receptors, CCR5/genetics/*physiology | 2 | 28.0 |
HIV-1/isolation & purification/*pathogenicity/physiology | 2 | 100.0 |
Gene Expression/drug effects | 2 | 0.0 |
HIV Envelope Protein gp120/metabolism | 2 | 1.0 |
Viral Envelope Proteins/*metabolism | 2 | 4.0 |
HIV-1/*metabolism/pathogenicity | 2 | 10.0 |
Cell Fusion/physiology | 2 | 22.0 |
SIV/*physiology | 2 | 7.0 |
Chemotaxis/physiology | 2 | 6.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Receptors, Chemokine/biosynthesis/*metabolism | 2 | 40.0 |
GTP-Binding Proteins/*physiology | 2 | 1.0 |
*Cytotoxicity, Immunologic | 2 | 0.0 |
Brain/metabolism | 2 | 0.0 |
Macrophage Inflammatory Protein-1/*metabolism | 2 | 9.0 |
Brain Chemistry/*immunology | 2 | 33.0 |
Acquired Immunodeficiency Syndrome/*immunology | 2 | 0.0 |
Virus Replication/*drug effects | 2 | 1.0 |
Cell Movement/drug effects | 2 | 0.0 |
Receptors, CCR5/*biosynthesis/immunology | 2 | 33.0 |
Chemotactic Factors, Eosinophil/pharmacology | 2 | 50.0 |
Gene Products, env/physiology | 2 | 25.0 |
Membrane Fusion | 5 | 3.0 |
Microglia/metabolism/*virology | 2 | 40.0 |
CD4-Positive T-Lymphocytes | 2 | 0.0 |
Neutrophils/immunology/metabolism | 3 | 15.0 |
Interferon-alpha/pharmacology | 2 | 2.0 |
Transforming Growth Factor beta/pharmacology | 3 | 0.0 |
*SIV | 2 | 18.0 |
HIV Envelope Protein gp120/genetics/metabolism | 2 | 25.0 |
HIV-1/genetics/isolation & purification/*metabolism | 2 | 50.0 |
HIV Core Protein p24/metabolism | 2 | 5.0 |
RNA/genetics/metabolism | 2 | 1.0 |
CHO Cells/metabolism | 2 | 5.0 |
Chemotactic Factors, Eosinophil/metabolism | 3 | 50.0 |
Survival Rate | 2 | 0.0 |
Receptors, CXCR4 | 2 | 5.0 |
Receptors, Cytokine/*physiology | 3 | 11.0 |
Interferon Type II/biosynthesis | 2 | 0.0 |
Receptors, CCR5 | 5 | 10.0 |
Chemokines/metabolism/pharmacology | 2 | 100.0 |
Gene Products, env/metabolism | 2 | 3.0 |
Interleukin-5/metabolism | 3 | 17.0 |
Chemokines, CXC/*metabolism | 2 | 3.0 |
Nuclear Magnetic Resonance, Biomolecular | 2 | 1.0 |
Gene Frequency | 2 | 0.0 |
Polymorphism, Single Nucleotide/*genetics | 2 | 0.0 |
Cytokines/*metabolism | 2 | 0.0 |
Allergens/*immunology | 3 | 3.0 |
Interleukin-13/metabolism | 2 | 12.0 |
Th1 Cells/immunology/metabolism | 2 | 5.0 |
Chemokines, CC/antagonists & inhibitors | 2 | 66.0 |
Treatment Outcome | 2 | 0.0 |
Receptors, CXCR4/biosynthesis/genetics | 2 | 28.0 |
Receptors, Cytokine/biosynthesis/genetics | 2 | 33.0 |
Chemokines, CC/metabolism/pharmacology | 2 | 12.0 |
Eosinophils/cytology/drug effects/metabolism | 2 | 66.0 |
RNA/metabolism | 2 | 0.0 |
